ReviewEuropean journal of immunology2026
Shifting From Systemic to Precision-Targeted Complement Therapies: Opportunities and Hurdles.
Review in European journal of immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Complement Activation by Post-Translationally Modified Proteins: Links to Chronic Inflammation and Autoimmunity.Immunological reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The landscape of complement therapeutics has significantly broadened in recent years; systemically acting stoichiometric inhibitors against complement proteins across almost the entire complement cascade are now available. However, despite their unquestionable clinical success, several limitations remain, including increased infection risks, loss of physiological functions, and clinically observed breakthrough events. In addition, many complement diseases require lifelong treatment, further amplifying the overall healthcare burden and motivating the development of alternative concepts for more precision-based therapies. Given that many complement-associated diseases primarily manifest in specific body compartments, directing complement intervention to an organ, tissue, or even a particular cell type represents an important goal. In this article, we briefly delineate the status of approved complement therapeutics and review preclinical progress in emerging concepts. We highlight several key properties that are essential for achieving targeted complement therapies: administration routes, tissue/cell penetration, specificity, and the mode of action. In addition to approaches aimed at dampening complement activation, we outline strategies designed to specifically activate complement locally, for example, in the context of cancer. Together, these insights underscore the growing potential of next-generation complement therapeutics to achieve more precise and effective clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.